Eagle Wealth Strategies’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$228K Hold
3,953
0.09% 104
2026
Q1
$240K Sell
3,953
-88
-2% -$5.13K 0.11% 92
2025
Q4
$218K Buy
+4,041
New +$194K 0.1% 100
2025
Q2
Sell
-3,912
Closed -$239K 106
2025
Q1
$239K Hold
3,912
0.15% 80
2024
Q4
$221K Hold
3,912
0.16% 93
2024
Q3
$202K Buy
+3,912
New +$184K 0.15% 101
2024
Q2
Sell
-3,912
Closed -$207K 91
2024
Q1
$207K Hold
3,912
0.17% 87
2023
Q4
$201K Buy
+3,912
New +$205K 0.12% 93

Other funds holding BMY

Eagle Wealth Strategies's BMY Position: Q2 2026 in Review

Eagle Wealth Strategies held its Bristol-Myers Squibb (BMY) position steady in Q2 2026 at 3,953 shares worth $228K. The position accounts for 0.09% of the portfolio, ranked #104.

Eagle Wealth Strategies first reported a position in BMY in Q4 2023 and has held it in 8 quarters since. The position peaked at $240K in Q1 2026. 831 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Eagle Wealth Strategies held 3,953 shares of Bristol-Myers Squibb worth $228K as of Q2 2026.
  • Eagle Wealth Strategies left its Bristol-Myers Squibb share count unchanged in Q2 2026.
  • Bristol-Myers Squibb made up 0.09% of Eagle Wealth Strategies's portfolio in Q2 2026, its #104 holding.
  • Eagle Wealth Strategies first reported a position in Bristol-Myers Squibb in Q4 2023 and has held it in 8 quarters since.
  • Eagle Wealth Strategies's Bristol-Myers Squibb position peaked at $240K in Q1 2026.
  • 831 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Eagle Wealth Strategies's 13F filing for Q2 2026, filed 9 Jul 2026.